Fusion Biopsy Market Size & Share Analysis - Growth Trends & Forecast (2025 - 2030)

The Fusion Biopsy Market Report is Segmented by Product Type (Equipment, Consumables), Route (Transrectal, Transperineal), End-User (Hospitals, Diagnostics Centers, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

Fusion Biopsy Market Size and Share

Compare market size and growth of Fusion Biopsy Market with other markets in Healthcare Industry

Fusion Biopsy Market Analysis

The Fusion Biopsy Market size is estimated at USD 0.82 billion in 2025, and is expected to reach USD 1.21 billion by 2030, at a CAGR of 8.06% during the forecast period (2025-2030).

The growth of the global fusion biopsy market is primarily fueled by the rising global incidence of prostate cancer and the increasing demand for precise, minimally invasive diagnostic solutions. Fusion biopsy systems, which combine MRI and real-time ultrasound for targeted sampling, offer enhanced diagnostic accuracy and significantly reduce false-negative rates—key factors for detecting and staging clinically significant prostate malignancies.

The World Health Organization’s Cancer Report (October 2024) projects a 39% global rise in prostate cancer cases by 2040, reflecting a significant public health concern. In Europe, the European Association of Urology’s 2024 Annual Report states that prostate cancer accounts for 27% of all new male cancer diagnoses, underscoring its significant burden on healthcare systems across the continent. According to GLOBOCAN 2024, prostate cancer ranks as the leading male cancer diagnosis in 118 countries worldwide, reflecting the widespread and growing need for accurate diagnostic tools in both developed and emerging economies.

Earlier, in December 2023, NHS Digital Statistics (UK) reported 55,033 new cases of prostate cancer in England, a 25% increase since 2019, further emphasizing the escalating disease burden. This pronounced uptick in prostate cancer incidence—driven by an aging global population, greater disease awareness, and strengthened healthcare infrastructure—is directly influencing the demand for fusion biopsy systems. These systems are increasingly being integrated into urology practices worldwide to improve diagnostic precision, enable early intervention, and ultimately enhance patient outcomes.

Despite the momentum, high costs associated with fusion biopsy systems and procedures remain a significant barrier to broader market penetration, especially in low-resource and price-sensitive settings. Nevertheless, ongoing technological advancements, expanding reimbursement support, and focused efforts to enhance accessibility are expected to overcome these challenges. As stakeholders work to scale adoption and drive down costs, the global fusion biopsy market is poised for robust growth over the forecast period.

Fusion Biopsy Industry Overview

The fusion biopsy market is moderately consolidated, with a few key players accounting for a significant share of the market. Intense competition among these market players is driven by the need to innovate and meet the growing demand for advanced diagnostic tools in prostate cancer management. This competitive landscape also creates opportunities for new entrants to establish their presence.

To bolster their market stance, companies pursue strategies like mergers, product launches, collaborations, expanding distribution networks, and venturing into developing regions. Additionally, investments in research and development to enhance biopsy accuracy and efficiency are gaining traction. These efforts aim to cater to the rising demand for minimally invasive diagnostic solutions, further intensifying competition in the market. 

Key international players—including Canon, Inc., FUJIFILM Holdings Corporation, GE Healthcare, Koninklijke Philips N.V., and Koelis command significant market shares due to their strong portfolios in imaging equipment. This competitive landscape fosters innovation and ensures a dynamic market environment, driven by the global rise in prostate cancer.

Fusion Biopsy Industry Leaders

  1. Canon Inc.

  2. FUJIFILM Holdings Corporation

  3. GE Healthcare

  4. Koninklijke Philips N.V.

  5. Koelis

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Fusion Biopsy Market News

  • September 2024: Koelis SAS introduced a compact 3D transducer for transperineal fusion biopsy and treatment. The device integrates with major high-level disinfection systems, improving safety and usability in clinical environments.
  • July 2024: In a pioneering move, Sir HN Reliance Foundation Hospital has introduced Indian state Maharashtra's inaugural MR fusion biopsy machine. This advanced equipment, leveraging MRI guidance, enhances the precision of prostate treatments. The MR Fusion Biopsy machine seamlessly integrates MRI visuals with ultrasound technology, harnessing artificial intelligence (AI) to pinpoint cancerous regions within a patient's body.
  • January 2024: Quibim introduced QP-Prostate, an AI-driven tool for prostate cancer detection. The product received CE and UKCA certifications, enhancing its credibility and adoption in European markets. Its AI algorithm identifies and stratifies intermediate and high-grade aggressive prostate cancer lesions, while also segmenting the prostate to enhance diagnostic accuracy and fusion biopsy planning. The results can be directly exported for fusion biopsy procedures.

Table of Contents for Fusion Biopsy Industry Report

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Prostate Cancer
    • 4.2.2 Availability of Reimbursements and Investments by the Public and Private Sectors
    • 4.2.3 Rising Adoption of Minimally Invasive Surgery
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Fusion Biopsy Systems and Procedures
    • 4.3.2 Limited Availability of Skilled Professionals
  • 4.4 Supply Chain Analysis
  • 4.5 Technology Outlook
  • 4.6 Porter's Five Force Analysis
    • 4.6.1 Threat of New Entrants
    • 4.6.2 Bargaining Power of Buyers/Consumers
    • 4.6.3 Bargaining Power of Suppliers
    • 4.6.4 Threat of Substitute Products
    • 4.6.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value)

  • 5.1 By Product Type
    • 5.1.1 Equipment
    • 5.1.2 Consumables
  • 5.2 By Route
    • 5.2.1 Transrectal
    • 5.2.2 Transperineal
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Diagnostic Centers
    • 5.3.3 Ambulatory Surgical Centers
    • 5.3.4 Others
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bobot Surgicals
    • 6.1.2 Canon Inc.
    • 6.1.3 Eigen Health
    • 6.1.4 Esaote Spa
    • 6.1.5 Exact Imaging
    • 6.1.6 Focal Healthcare
    • 6.1.7 FUJIFILM Holdings Corporation
    • 6.1.8 GE Healthcare
    • 6.1.9 Hitachi, Ltd.
    • 6.1.10 Koelis
    • 6.1.11 Koninklijke Philips N.V
    • 6.1.12 Medcom
    • 6.1.13 MTT GmbH
    • 6.1.14 Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
    • 6.1.15 UC-Care Medical Systems
  • *List Not Exhaustive
  • 6.2 Company Share Analysis
  • 6.3 Competitive Benchmarking

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Fusion Biopsy Market Report Scope

As per the report's scope, fusion biopsy refers to the usage of medical devices, software platforms, and consumables for image-fusion-guided biopsy procedures, primarily for prostate cancer diagnosis. The technology combines pre-acquired magnetic resonance imaging data with real-time ultrasound imaging to generate a three-dimensional anatomical map of the prostate, enabling precise targeting of suspicious lesions during biopsy procedures.

The fusion biopsy market is segmented by product type, route, end-user, and geography. By product type, the market is segmented into equipment and consumables. On the basis of route, the market is segmented into transrectal and transperineal. Based on end-users, the market is segmented into hospitals, diagnostic centers, ambulatory surgical centers, and others. The market is geographically segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. The report also provides market size and forecasts for 17 countries across these regions, with revenue (USD) serving as the basis for projections in each segment.

By Product Type Equipment
Consumables
By Route Transrectal
Transperineal
By End-User Hospitals
Diagnostic Centers
Ambulatory Surgical Centers
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Equipment
Consumables
By Route
Transrectal
Transperineal
By End-User
Hospitals
Diagnostic Centers
Ambulatory Surgical Centers
Others
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

How big is the Fusion Biopsy Market?

The Fusion Biopsy Market size is expected to reach USD 0.82 billion in 2025 and grow at a CAGR of 8.06% to reach USD 1.21 billion by 2030.

What is the current Fusion Biopsy Market size?

In 2025, the Fusion Biopsy Market size is expected to reach USD 0.82 billion.

Who are the key players in Fusion Biopsy Market?

Canon Inc., FUJIFILM Holdings Corporation, GE Healthcare, Koninklijke Philips N.V. and Koelis are the major companies operating in the Fusion Biopsy Market.

Which is the fastest growing region in Fusion Biopsy Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Fusion Biopsy Market?

In 2025, the North America accounts for the largest market share in Fusion Biopsy Market.

What years does this Fusion Biopsy Market cover, and what was the market size in 2024?

In 2024, the Fusion Biopsy Market size was estimated at USD 0.75 billion. The report covers the Fusion Biopsy Market historical market size for years: 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Fusion Biopsy Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Fusion Biopsy Industry Report

Statistics for the 2025 Fusion Biopsy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Fusion Biopsy analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Access Report